WO1991019711A1 - Benzimidazoles substitues, procede de preparation et utilisation pharmaceutique de ceux-ci - Google Patents

Benzimidazoles substitues, procede de preparation et utilisation pharmaceutique de ceux-ci Download PDF

Info

Publication number
WO1991019711A1
WO1991019711A1 PCT/SE1991/000415 SE9100415W WO9119711A1 WO 1991019711 A1 WO1991019711 A1 WO 1991019711A1 SE 9100415 W SE9100415 W SE 9100415W WO 9119711 A1 WO9119711 A1 WO 9119711A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
compound
formula
pyridinyl
dimethoxy
Prior art date
Application number
PCT/SE1991/000415
Other languages
English (en)
Inventor
Arne Elof BRÄNDSTRÖM
Per Lennart Lindberg
Gunnel Elisabeth SUNDéN
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Priority to AU80097/91A priority Critical patent/AU649453B2/en
Priority to JP91511435A priority patent/JPH05507713A/ja
Priority to RO92-01581A priority patent/RO110493B1/ro
Publication of WO1991019711A1 publication Critical patent/WO1991019711A1/fr
Priority to NO92924775A priority patent/NO924775L/no
Priority to FI925766A priority patent/FI925766A0/fi
Priority to BG097200A priority patent/BG97200A/bg
Priority to LV931045A priority patent/LV10953A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

On décrit les nouveaux composés de formule (I), où R1 et R2, qui sont différents, représentent chacun H, un alkyle contenant de 1 à 4 atomes de carbone ou -C(O)-R6; l'un d'entre R1 et R2 est toujours choisi dans le groupe -C(O)-R?6; où R6¿ représente un alkyle contenant de 1 à 4 atomes de carbone ou un alcoxy contenant de 1 à 4 atomes de carbone, R3 représente le groupe -CH¿2?OCOOR?7, où R7¿ représente un alkyle contenant de 1 à 6 atomes de carbone ou un benzyle; R4 et R5 sont les mêmes ou différents et choisis à partir de -CH¿3?, -C2H5, (a), (b) et -CH2CH2OCH3, ou R?4 et R5¿ forment un cycle avec les atomes d'oxygène contigus rattachés au cycle pyridique et les atomes de carbone dans le cycle pyridique, où la partie composée de R4 et R5 représente -CH¿2?CH2CH2-, -CH2CH2- ou -CH2-. On décrit aussi des compositions pharmaceutiques contenant de tels composés comme ingrédient actif et l'utilisation de ces composés dans le domaine médical.
PCT/SE1991/000415 1990-06-20 1991-06-11 Benzimidazoles substitues, procede de preparation et utilisation pharmaceutique de ceux-ci WO1991019711A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU80097/91A AU649453B2 (en) 1990-06-20 1991-06-11 Substituted benzimidazoles, process for their preparation and their pharmaceutical use
JP91511435A JPH05507713A (ja) 1990-06-20 1991-06-11 置換ベンズイミダゾール、その製造方法およびその薬学的使用
RO92-01581A RO110493B1 (ro) 1990-06-20 1991-06-11 Derivati de benzimidazol si procedee pentru prepararea acestora
NO92924775A NO924775L (no) 1990-06-20 1992-12-10 Substituerte benzimidazoler, fremgangsmaate for deres fremstilling og deres farmasoeytiske anvendelse
FI925766A FI925766A0 (fi) 1990-06-20 1992-12-18 Substituerade bensimidazoler, foerfarande foer deras framstaellning och deras farmaceutiska anvaendning
BG097200A BG97200A (bg) 1990-06-20 1992-12-18 Заместени бензимидазоли,метод за получаването им и тяхното фармацевтично приложение
LV931045A LV10953A (lv) 1990-06-20 1993-08-27 Aizvietotie benzimidazoli to iegusanas panemiens pielietojums farmaceitiska kompozicija

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002206A SE9002206D0 (sv) 1990-06-20 1990-06-20 New compounds
SE9002206-2 1990-06-20

Publications (1)

Publication Number Publication Date
WO1991019711A1 true WO1991019711A1 (fr) 1991-12-26

Family

ID=20379831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000415 WO1991019711A1 (fr) 1990-06-20 1991-06-11 Benzimidazoles substitues, procede de preparation et utilisation pharmaceutique de ceux-ci

Country Status (27)

Country Link
EP (1) EP0535081A1 (fr)
JP (1) JPH05507713A (fr)
CN (1) CN1058212A (fr)
AP (1) AP215A (fr)
AU (1) AU649453B2 (fr)
BG (1) BG97200A (fr)
CA (1) CA2083714A1 (fr)
CZ (1) CZ279772B6 (fr)
FI (1) FI925766A0 (fr)
HU (1) HUT62881A (fr)
IE (1) IE912025A1 (fr)
IL (1) IL98470A0 (fr)
IS (1) IS3721A7 (fr)
LT (2) LT3952B (fr)
LV (1) LV10953A (fr)
MA (1) MA22199A1 (fr)
NO (1) NO924775L (fr)
NZ (1) NZ238546A (fr)
OA (1) OA09682A (fr)
PT (1) PT98035A (fr)
RO (1) RO110493B1 (fr)
SE (1) SE9002206D0 (fr)
TN (1) TNSN91049A1 (fr)
TW (1) TW216418B (fr)
WO (1) WO1991019711A1 (fr)
YU (1) YU104191A (fr)
ZA (2) ZA914297B (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015962A1 (fr) * 1993-12-06 1995-06-15 Astra Aktiebolag Benzimidazole subtitue, ses procedes de preparation et son utilisation pharmaceutique
AU665043B2 (en) * 1991-12-19 1995-12-14 Astra Aktiebolag Substituted benzimidazoles, process for their preparation as well as their use
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US6136344A (en) * 1995-02-06 2000-10-24 Astra Aktiebolag Oral pharmaceutical dosage form
US6617338B2 (en) 2000-02-24 2003-09-09 Kopran Research Laboratories Limited Orally administrable acid stable antiulcer benzimidazole derivatives
WO2004035090A1 (fr) 2002-10-16 2004-04-29 Orexo Ab Composition inhibant la secretion d'acide gastrique
WO2008012621A2 (fr) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions et procédés d'inhibition de sécrétion d'acide gastrique utilisant des dérivés de petits acides dicarboxyliques combinés á un ipp
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7815940B2 (en) 2001-04-18 2010-10-19 Orexo Ab Gastric acid secretion inhibiting composition
EP2275139A1 (fr) 1996-01-08 2011-01-19 AstraZeneca AB Formes galéniques pharmaceutiques orales comprenant un inhibiteur de pompe à protons et un anti-inflammatoire non stéroidien
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US8226979B2 (en) 2003-09-26 2012-07-24 Alza Corporation Drug coating providing high drug loading and methods for providing the same
EP2601938A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Compositions pharmqaceutiques pour le traitement de maladies associées à Hélicobacter pylori
KR101285696B1 (ko) * 2005-04-15 2013-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 화합물
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8852636B2 (en) 2001-06-01 2014-10-07 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8945621B2 (en) 2009-06-25 2015-02-03 Pozen Inc. Method for treating a patient at risk for developing an NSAID-associated ulcer
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US9814684B2 (en) 2002-04-09 2017-11-14 Flamel Ireland Limited Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2021200290B2 (en) * 2016-09-14 2023-09-14 National Health Research Institutes Novel substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
WO2007122686A1 (fr) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Composes benzimidazole
JP5492417B2 (ja) * 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176308A2 (fr) * 1984-09-24 1986-04-02 The Upjohn Company 2-(Pyridylalkylènesulfinyle)-benzimidazoles
EP0221041A2 (fr) * 1985-10-29 1987-05-06 Aktiebolaget Hässle Dérivés de benzimidazole, leur préparation et leur application comme médicaments

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418966B (sv) 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IN148930B (fr) 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
CH644116A5 (de) 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US4738975A (en) 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
NZ222495A (en) 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
DE3722810A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Substituierte benzimidazole, verfahren zu deren herstellung, diese enthaltende pharmazeutische zubereitungen und deren verwendung
JPH02501930A (ja) * 1987-10-30 1990-06-28 アクチエボラゲツト・ヘツスレ 薬学的化合物のための新規な用途
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
WO1989011479A1 (fr) * 1988-05-25 1989-11-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux composes fluores d'alkoxyde

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0176308A2 (fr) * 1984-09-24 1986-04-02 The Upjohn Company 2-(Pyridylalkylènesulfinyle)-benzimidazoles
EP0221041A2 (fr) * 1985-10-29 1987-05-06 Aktiebolaget Hässle Dérivés de benzimidazole, leur préparation et leur application comme médicaments

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665043B2 (en) * 1991-12-19 1995-12-14 Astra Aktiebolag Substituted benzimidazoles, process for their preparation as well as their use
WO1995015962A1 (fr) * 1993-12-06 1995-06-15 Astra Aktiebolag Benzimidazole subtitue, ses procedes de preparation et son utilisation pharmaceutique
US6136344A (en) * 1995-02-06 2000-10-24 Astra Aktiebolag Oral pharmaceutical dosage form
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
EP2275139A1 (fr) 1996-01-08 2011-01-19 AstraZeneca AB Formes galéniques pharmaceutiques orales comprenant un inhibiteur de pompe à protons et un anti-inflammatoire non stéroidien
US6617338B2 (en) 2000-02-24 2003-09-09 Kopran Research Laboratories Limited Orally administrable acid stable antiulcer benzimidazole derivatives
US7815940B2 (en) 2001-04-18 2010-10-19 Orexo Ab Gastric acid secretion inhibiting composition
EP2253309A2 (fr) 2001-04-18 2010-11-24 Orexo AB Composition inhibant la secretion d'acides gastriques
US9364439B2 (en) 2001-06-01 2016-06-14 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9198888B2 (en) 2001-06-01 2015-12-01 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8858996B2 (en) 2001-06-01 2014-10-14 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDS
US8865190B2 (en) 2001-06-01 2014-10-21 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9161920B2 (en) 2001-06-01 2015-10-20 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8852636B2 (en) 2001-06-01 2014-10-07 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9345695B2 (en) 2001-06-01 2016-05-24 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9707181B2 (en) 2001-06-01 2017-07-18 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9814684B2 (en) 2002-04-09 2017-11-14 Flamel Ireland Limited Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US10004693B2 (en) 2002-04-09 2018-06-26 Flamel Ireland Limited Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2004035090A1 (fr) 2002-10-16 2004-04-29 Orexo Ab Composition inhibant la secretion d'acide gastrique
EP2258341A2 (fr) 2002-10-16 2010-12-08 Orexo AB Composition d'inhibition de sécrétion d'acide gastrique
US7771747B2 (en) 2002-10-16 2010-08-10 Orexo Ab Gastric acid secretion inhibiting composition
US7785626B2 (en) 2002-10-16 2010-08-31 Orexo Ab Gastric acid secretion inhibiting composition
US8226979B2 (en) 2003-09-26 2012-07-24 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR101285696B1 (ko) * 2005-04-15 2013-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 화합물
NO339502B1 (no) * 2005-04-15 2016-12-19 Eisai R&D Man Co Ltd Benzimidazolforbindelser
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US9132082B2 (en) 2005-05-11 2015-09-15 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US9370481B2 (en) 2005-05-11 2016-06-21 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US9278080B2 (en) 2005-05-11 2016-03-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US9233092B2 (en) 2006-07-25 2016-01-12 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2008012621A2 (fr) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions et procédés d'inhibition de sécrétion d'acide gastrique utilisant des dérivés de petits acides dicarboxyliques combinés á un ipp
US9801824B2 (en) 2008-09-09 2017-10-31 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9393208B2 (en) 2008-09-09 2016-07-19 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US8945621B2 (en) 2009-06-25 2015-02-03 Pozen Inc. Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
EP2601938A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Compositions pharmqaceutiques pour le traitement de maladies associées à Hélicobacter pylori
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US9987231B2 (en) 2011-12-28 2018-06-05 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US10603283B2 (en) 2011-12-28 2020-03-31 Genus Lifesciences, Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
AU2021200290B2 (en) * 2016-09-14 2023-09-14 National Health Research Institutes Novel substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors

Also Published As

Publication number Publication date
SE9002206D0 (sv) 1990-06-20
HUT62881A (en) 1993-06-28
EP0535081A1 (fr) 1993-04-07
LV10953A (lv) 1995-12-20
IS3721A7 (is) 1991-12-21
YU104191A (sh) 1994-01-20
FI925766A (fi) 1992-12-18
AP9100285A0 (en) 1991-07-31
LT3977B (en) 1996-06-25
CA2083714A1 (fr) 1991-12-21
TW216418B (fr) 1993-11-21
ZA914296B (en) 1992-03-25
HU9204033D0 (en) 1993-03-29
PT98035A (pt) 1992-03-31
CZ279772B6 (cs) 1995-06-14
BG97200A (bg) 1993-12-24
OA09682A (en) 1993-05-15
AU8009791A (en) 1992-01-07
LT3952B (en) 1996-05-27
AP215A (en) 1992-09-02
RO110493B1 (ro) 1996-01-30
NZ238546A (en) 1994-03-25
LTIP1713A (en) 1995-08-25
CS189491A3 (en) 1992-04-15
IE912025A1 (en) 1992-01-01
MA22199A1 (fr) 1992-04-01
LTIP1712A (en) 1995-08-25
TNSN91049A1 (fr) 1992-10-25
FI925766A0 (fi) 1992-12-18
ZA914297B (en) 1992-03-25
AU649453B2 (en) 1994-05-26
CN1058212A (zh) 1992-01-29
NO924775D0 (no) 1992-12-10
NO924775L (no) 1992-12-10
IL98470A0 (en) 1992-07-15
JPH05507713A (ja) 1993-11-04

Similar Documents

Publication Publication Date Title
AP215A (en) Substituted benzimidazoles, process for their preparation and their pharmaceutical use.
EP0593463B1 (fr) Derives de dialcoxy-pyridinyle-benzimidazole, procede de preparation et utilisation pharmaceutique de ces derives
EP0449940B1 (fr) Nouveau compose therapeutiquement actif et son procede de preparation
US4965269A (en) Therapeutically active chloro substituted benzimidazoles
EP0451188B1 (fr) Benzimidazole therapeutiquement actif a substitution et son procede de preparation
EP0449935B1 (fr) Compose a effet inhibiteur d'acide gastrique et son procede de preparation
WO1987005021A1 (fr) Benzimidazoles et utilisation pharmaceutique desdits benzimidazoles
WO1995015962A1 (fr) Benzimidazole subtitue, ses procedes de preparation et son utilisation pharmaceutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991911659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2083714

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 925766

Country of ref document: FI

Ref document number: 92-01581

Country of ref document: RO

WWP Wipo information: published in national office

Ref document number: 1991911659

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1991911659

Country of ref document: EP